USANA Health Sciences

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

USANA Health Sciences addresses challenges, eyes growth through cost management

USANA Health Sciences navigated a challenging operating environment by focusing on cost management, product demand trends, and growth strategies. Despite facing headwinds in China and Southeast Asia, the company remains resilient and poised for opportunities in new markets and acquisitions.

USANA Health Sciences reports solid Q1 results amid global challenges

USANA Health Sciences delivered strong Q1 results amidst global challenges, driven by robust demand for health products.
Strategic leadership transition and focus on cost management position the company for sustained growth and operational efficiency.
Opportunities in China market, new market launches, and enhanced customer engagement strategies offer avenues for future expansion.

USANA Health Sciences exceeds Q2 expectations, eyes India expansion

USANA Health Sciences delivered strong Q2 results with a focus on sustainable growth strategies and expansion into new markets. Challenges include tough year-over-year comparisons and cash flow impact from accrued liabilities.

USANA Health Sciences addresses challenges, eyes India expansion for growth

USANA Health Sciences navigated challenges in Q3 2023 with a focus on addressing operational hurdles and driving growth through strategic initiatives. The company's restructuring and expansion into India signal a commitment to long-term success and capitalizing on emerging opportunities.

USANA Health Sciences exceeds Q4 expectations, eyes global growth

USANA Health Sciences delivered strong performance in Q4 2023, driven by growth in Greater China and a solid financial position. While facing challenges such as currency fluctuations and market-specific issues, the company is well-positioned to capitalize on opportunities through strategic initiatives and market tailoring. By focusing on sustainable growth and innovation, USANA aims to further strengthen its market presence and drive profitability.

USANA Health Sciences reports mixed Q1 results, eyes growth strategies

USANA Health Sciences faced mixed results in Q1 2024, with Mainland China driving growth while other markets struggled. The company is addressing challenges through market-specific incentives and focusing on future strategies like product development and localization.

USANA Health Sciences adapts to market challenges with strategic focus

USANA Health Sciences navigated macroeconomic challenges by implementing strategic initiatives and restructuring its commercial team.
The company's focus on product innovation, market expansion into India, and leadership additions signal a commitment to sustainable success.
While facing challenges in market conditions, USANA aims to leverage opportunities like M&A activities and accelerated product development for growth.

USANA Health Sciences adapts strategies to drive growth amid challenges

USANA Health Sciences faced challenges in Q3 with lower-than-expected net sales, particularly in China, but is implementing strategies to boost performance.
The company's strengths in product innovation, streamlined development processes, and strong product lineup position it well for future growth.
Addressing challenges such as decreased average spend and revised guidance presents opportunities for USANA to enhance revenue and market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, Dec. 30, 2020 /PRNewswire/ -- USANA, a leader in cellular nutrition, has once again been recognized with a seal of approval by renowned, third-party assessor ConsumerLab.com—this time for its omega-3 supplement, BiOmega. This ultrapure fish-oil supplement supports...

USANA BiOmega supplement is of-fish-ially ConsumerLab.com approved

It has no debt and is selling at a steep discount to its previous highs, but is Usana Health Sciences Inc. (NYSE:USNA) a good value stock for the next five to 10 years? I have to ask because the share price has not recovered since peaking and falling in 2018:

Is Debt-Free Usana a Good Value Stock?

SALT LAKE CITY, Dec. 28, 2020 /PRNewswire/ -- USANA, a leader in cellular nutrition, is well-known for its quality supplements and long list of awards— including a recent award from the Asia Pacific Enterprise Awards (APEA). The company's Philippines market earned top recognition at the...

USANA Philippines receives top honors by Asia Pacific Enterprise Awards

Intel

MAXIMUS

SEI Investments

According to the Peter Lynch Stalwarts Screen, a Premium All-in-One Screener template, four stocks that have good growth potential and are modestly undervalued based on the GF Value measure are Intel Corp. (NASDAQ:INTC), Maximus Inc. (NYSE:MMS), SEI Investments Co. (NASDAQ:SEIC) and Usana Health Sciences Inc. (NYSE:USNA).

4 Modestly Undervalued Stalwarts as of December

SALT LAKE CITY--(BUSINESS WIRE)--USANA (NYSE: USNA), a leader in cellular nutrition, today announced that it has entered into a strategic investment and collaboration with Built Brands, a leading manufacturer and distributor of protein bars. USANA has made a minority equity investment in Built Brands, enabling USANA to leverage Built Brands' expertise to accelerate the development, enhancement and expansion of USANA's offering of healthy nutrition bars that will be manufactured in USANA's new f

USANA Announces Strategic Collaboration with Built Brands

Is USANA Health Sciences (USNA) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick USANA Health (USNA) Stock Now?

SALT LAKE CITY, Oct. 26, 2020 /PRNewswire/ -- To be recognized as the top company in your industry is an honor few achieve—one USANA Malaysia has earned for the second year in a row. USANA was recently named the No. 1 Combination Dietary Supplements Brand in Malaysia by Euromonitor...

USANA Malaysia named number one combination dietary supplements brand in the country by world-leading market research company

Is (USNA) Outperforming Other Medical Stocks This Year?

Is USANA Health Sciences (USNA) Stock Outpacing Its Medical Peers This Year?

USANA Health Sciences' (USNA) CEO Kevin Guest on Q3 2020 Results - Earnings Call Transcript

USANA Health (USNA) delivered earnings and revenue surprises of 11.63% and 5.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Q3 Earnings and Revenues Top Estimates

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 26, 2020. Key Financial & Operating Highlights Third quarter net sales increased 14.5% year-over-year to $298.5 million due to strong product demand and successful incentive programs. Diluted EPS increased 32.1% year-over-year to a record $1.44. Active customers increased 16.5% year-over-year to a record 650,000. Company raises full-year 20

USANA Health Sciences Reports Strong Third Quarter Growth; Raises Full-Year 2020 Net Sales and EPS Outlook

On Tuesday, October 20, Usana Health Sciences (NYSE: USNA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Preview: Usana Health Sciences's Earnings

AMC Networks

Noah Holdings Ltd.

Stellus Capital Investment Corp 5.75 % Notes 2017-15.09.22

Gray TV

The following cyclical companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of Oct. 5, all of them also trade with a margin of safety.

5 Guru Stocks Boosting Earnings

PC Connection

Gorman-Rupp

Power Integrations

According to the All-in-One Screener's Historical Data Screen, a Premium Plus feature of GuruFocus, four Russell 2000 companies that have shown high financial strength over the past few years include Usana Health Sciences Inc.

4 Russell 2000 Companies With High Financial Strength

Buckle

National Presto Industries

Investors who are seeking value opportunities may be interested in the following stocks, as they have low price-sales ratios, high profitability and robust financials.

A Trio of Stocks With Low Price-Sales Ratios to Consider

Blackrock Inc

SPS Commerce

TriNet Group

Markets set the stage for a higher open this morning as investors looked to snap up some discounted stocks after several days of heavy losses, especially in the Technology sector. For investors looking to capitalize on this correction, our deep learning algorithms have determined today's Top Buys.

Top Stocks To Buy Today As Dow Receives Boost From Tech Recovery

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of John T.

USANA Health Sciences Announces Appointment of John T. Fleming to Board of Directors

SALT LAKE CITY, Aug. 17, 2020 /PRNewswire/ -- Managing occasional stress and keeping a calm mind are vital for navigating today's world.

USANA launches new, cutting-edge Mood and Relaxation product line at Americas and Europe Virtual Convention

Is  (USNA) Outperforming Other Medical Stocks This Year?

Has USANA Health Sciences (USNA) Outpaced Other Medical Stocks This Year?

SALT LAKE CITY, Aug. 10, 2020 /PRNewswire/ -- Strong leadership is the key to corporate success, especially for a company like USANA, which operates in 24 different markets around the world.

USANA executive named as one of the most outstanding leaders in Asia by renowned organization

USANA Health Science shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
The post USANA Health Science Trying To Close In On Key Technical Benchmark appeared first on Investor's Business Daily.

USANA Health Science Trying To Close In On Key Technical Benchmark

USANA Health Sciences Inc. (USNA) CEO Kevin Guest on Q2 2020 Results - Earnings Call Transcript

USANA Health (USNA) delivered earnings and revenue surprises of 10.92% and -3.29%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Tops Q2 Earnings Estimates

USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.

USANA (USNA) to Report Q2 Earnings: What's in the Cards?

As of late, it has definitely been a great time to be an investor of USANA Health Sciences

News for USANA Health Sciences Stock (USNA)